Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At ...
On July 3, 2025, a Citizen’s Petition was filed with the U.S. Food and Drug Administration in which the petitioners, a group consisting mostly of amyotrophic lateral sclerosis (ALS) patients who have ...
The average one-year price target for Brainstorm Cell Therapeutics (NasdaqCM:BCLI) has been revised to 2.55 / share. This is an increase of 150.00% from the prior estimate of 1.02 dated March 28, 2024 ...
) has been revised to $17.34 / share. This is a decrease of 13.95% from the prior estimate of $20.15 dated September 27, 2025. The price target is an average of many targets provided by analysts. The ...
READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE – NEURODEGENERATIVE DISEASE STEM CELLS & ALS/MND/LOU GEHRIG'S HERE Post hoc analysis of BCLI's PIII early stage (mild ...
READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE – NEURODEGENERATIVE DISEASE STEM CELLS & ALS/MND/LOU GEHRIG'S HERE Why is BCLI's PIIIb trial advantageous to ...
Brainstorm Cell Therapeutics (NASDAQ: BCLI) stock is up 47% premarket. BCLI stock rising is one of those things that a sober reading of the objective evidence would not lead us to expect. Therefore we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results